Cationic antimicrobial peptides (AMPs) are an intrinsic part of the human innate immune system. Over 100 different human AMPs are known to exhibit broad-spectrum antibacterial activity. Because of the increased frequency of resistance to conventional antibiotics there is an interest in developing AMPs as an alternative antibacterial therapy. Several cationic peptides that are derivatives of AMPs from the human innate immune system are currently in clinical development. There are also ongoing clinical studies aimed at modulating the expression of AMPs to boost the human innate immune response. In this review we discuss the potential problems associated with these therapeutic approaches. There is considerable experimental data describing mechanisms by which bacteria can develop resistance to AMPs. As for any type of drug resistance, the rate by which AMP resistance would emerge and spread in a population of bacteria in a natural setting will be determined by a complex interplay of several different factors, including the mutation supply rate, the fitness of the resistant mutant at different AMP concentrations, and the strength of the selective pressure. Several studies have already shown that AMP-resistant bacterial mutants display broad cross-resistance to a variety of AMPs with different structures and modes of action. Therefore, routine clinical administration of AMPs to treat bacterial infections may select for resistant bacterial pathogens capable of better evading the innate immune system. The ramifications of therapeutic levels of exposure on the development of AMP resistance and bacterial pathogenesis are not yet understood. This is something that needs to be carefully studied and monitored if AMPs are used in clinical settings.
Introduction to AMPs

Definition of AMPs and early history
Cationic antimicrobial peptides (AMPs) are relatively small peptides that, by definition, have a net positive charge, and exhibit some, often broad-spectrum, antimicrobial activity. This rather tautological definition encompasses a great diversity of molecules, at both the sequence and the structural level. An online antimicrobial peptide database, APD3 , accessible at http://aps.unmc.edu/AP/, lists over 2600 examples of AMPs from all kingdoms of life: bacteria, archaea, and eukaryotes (including plants, animals, fungi and protists). AMPs can act directly to protect animals against a wide variety of bacterial, viral, fungal and protozoan infections and because of this are often referred to as host defense peptides. In animals, both vertebrates and invertebrates, AMPs also function as a universal and important part of the innate immune system, modulating activities that promote protection against infections by microorganisms. The APD3 database currently lists 112 different human host defense peptides of which 100 have experimentally determined antibacterial activities. The focus of this review is on the importance of human AMPs in protecting against bacterial infections, on the mechanisms of intrinsic and acquired bacterial resistance to AMPs, and on the opportunities and potential consequences associated with therapeutic use of AMPs.
AMPs are not unique as peptide-based small molecules with antibacterial activity. Many of the antibiotics produced by microorganisms are peptide-based molecules. These are produced by non-ribosomal peptide synthesis (NRPS), a process that involves the expression of large arrays of genes encoding multiple enzymes that work in succession to catalyze the sequence of chemical reactions required to synthetize the antibiotic (Baltz, 2006; Hughes, 2003) . Peptide-based antibiotics include ␤-lactams such as penicillin, cyclic peptide antibiotics like the polymixins and bacitracin, glycopeptides like vancomycin (Yim et al., 2014) , and the lipopeptide daptomycin, one of the most recently introduced novel antibiotic classes (Robbel and Marahiel, 2010) . The AMPs discussed in this review differ from peptide-based antibiotics in the mechanism of their synthesis and also in their amino acid make-up. AMPs, including those made in human cells, are in contrast to NRPS-antibiotics, produced by the normal process of ribosomal translation on an mRNA template. The primary product is usually a pre-protein that is then processed to the final length of the active AMP. For example, the human cathelicidin AMP, LL-37, is produced as a precursor protein, human cationic antimicrobial protein-18 kDa (hCAP18), and the mature LL-37 peptide is the result of its processing by proteinase 3 (Gudmundsson et al., 1996) . This difference in the genetic origins of AMPs and NRPS-antibiotics has consequences for the compositions of the final products. Ribosomally produced AMPs contain only the normal complement of amino acids found in proteins, sometimes with post-translational modifications. NRPS-produced antibiotics, in contrast, are unconstrained by the limitations of ribosomal translation, and usually contain a mixture of normal amino acids together with non-canonical amino acids not found in any proteins (Walsh et al., 2013) . In addition, genes for some of the human ␣-defensins (HNP1 and HNP3) are present in multiple copies and are inherited unequally by different individuals, giving rise to individuals with two or three copies of either or both of these genes, potentially affecting the levels of AMPs produced among individuals (Mars et al., 1995) .
Human AMPs vary in length from 5 to 149 amino acids (Bangalore et al., 1990; Cash et al., 2006) . The great majority are cationic peptides, but the net charge of different human AMPs ranges from −3 to +20. AMPs have been identified in different human excretions, tissues and cell types, including saliva, tears, sweat and milk, on the skin and tongue, in bone marrow, plasma, kidneys, liver, heart, brain, eyes, intestine, sperm, urinary tract, amniotic fluid, and respiratory tract, and in many different cell types including epithelial/mucosal cells, macrophages, neutrophils, natural killer cells, monocytes, eosinophilic leukocytes, Paneth cells, T-cells and B-cells (http://aps.unmc.edu/AP/ ). Research into the functions of AMPs goes back at least to the time of Alexander Fleming who discovered lysozyme (Fleming and Allison, 1922) . However, it is in the past few decades, especially after the discovery of cationic bacteriocidal peptides in polymorphonuclear leukocytes (Zeya and Spitznagel, 1963) , that interest and research has expanded explosively. During the 1990s important new classes of AMPs were discovered in humans, including the ␤-defensins (Bensch et al., 1995) and the cathelicidins (Gallo et al., 1997) and this stimulated research into understanding the number and variety of human AMPs and, more recently, into their potential applications in antimicrobial therapy to control bacterial infections.
Structures of AMPs
Defensins and cathelicidin were recognized early on as important components of the antimicrobial mechanisms of polymorphonuclear leukocytes (PMNs), and were classified as belonging to significantly different structural families (Lehrer and Ganz, 2002; Zanetti et al., 1995) . A classification of AMPs into four major families, based on their 3D structures, has been adopted by the APD3 database .
(i) The alpha family is composed of AMPs with helical structures, for example, the human cathelicidin LL-37 (Agerberth et al., 1995) . (ii) The beta family is composed of AMPs with ␤-strands, for example, the human ␣-defensins . (iii) The alphabeta family comprises AMPs with both ␣-helical and ␤-strands structures in the same 3D fold, for example, the human ␤-defensins (Harder et al., 1997) . The sequences of both the ␣-and ␤-defensins include six cysteine residues that stabilize the structure by forming three intramolecular disulfide bonds. ␤-Sheet AMPs are frequently cyclic molecules with the structure constrained by the intramolecular disulfide bridges. The ␣-and ␤-defensins differ in the bonding pattern of their cysteines, probably reflecting their different phylogenetic origins. In total, humans encode six different ␣-defensins, over 30 different ␤-defensins, but only one ␣-helical cathelicidin, LL-37 (Bauer and Shafer, 2015; Wang, 2014) . (iv) The non-alphabeta family contains AMPs with neither ␣-helical nor ␤-strands, for example, the antimicrobial peptide indolicidin, isolated from cattle (Selsted et al., 1992) . Because 3D structures are known for less than 400 of the over 2600 identified AMPs, this classification system should be regarded as provisional and other classification systems are concurrently in use, based on properties such as covalent bonding patterns, hydrophobicity, net charge, or molecular targets (Wang, 2015) .
AMP structure influences activity
The antibacterial properties of AMPs are associated with two interrelated features of the peptides: their net charge, which for the great majority of AMPs is positive, and their propensity to be amphipathic, meaning that they can fold into structures with both a hydrophobic and a hydrophilic surface. These features together facilitate the interaction of AMPs with the negatively charged components of the bacterial envelope (e.g., lipopolysaccharides (LPS) and techoic acids (TA)) on the surfaces of Gram-negative and Grampositive bacteria, respectively, and with the negatively charged phospholipids of the bacterial membrane (Morgera et al., 2008; Wang, 2008) . For example, AMPs like LL-37 are initially attracted to the bacterial surface by electrostatic interactions. LL-37 interacts with lipid bilayers such that the amphipathic helix is oriented parallel to the surface of the bilayer (Henzler Wildman et al., 2003) . It is widely believed that after the initial electrostatic interaction with the bacterial surface that the amphipathic nature of AMPs allows them to insert into the bacterial cell membrane, forming a pore that disrupts membrane integrity, leading to osmotic lysis of the bacterial cell. However, as discussed below, there is evidence that this view of the AMP antibacterial mode of action may be an oversimplification.
Biological roles of AMPs
Expression of AMPs
Human AMPs are expressed in a wide variety of cells of the immune system, including neutrophils, NK, and T cells, as well as in the epithelial cells lining tissues facing the external environment (Yang et al., 2004) . The expression of these AMPs can be constitutive (e.g. ␣-and ␤-defensins in neutrophils, and ␣-defensins in paneth cells), inducible (e.g. ␣-defensins in CD8T cells, ␤-defensins in epithelial cells) or both constitutive and inducible (e.g. cathelicidins and ␤-defensins in a variety of cells, including neutrophils, epithelial cells, and macrophages). Expression of most of the ␤-defensins is also induced by proinflammatory stimuli, including bacteria, LPS, TNF␣, and IL-1 (Diamond et al., 1996; Fang et al., 2003; Singh et al., 1998) .
Antibacterial activity (direct)
Human cathelicidin and human defensins have the capacity to kill a wide variety of Gram-positive and Gram-negative bacteria in vitro Garcia et al., 2001b; Harder et al., 2001 Harder et al., , 1997 Ouellette and Selsted, 1996; Zaiou et al., 2003) . Like small molecule antibiotics, this antibacterial activity of AMPs is dose-dependent and bacteriocidal activities are usually observed at M concentrations. Evidence for their antibacterial efficacy in vivo comes from studies using infections in animal models (Huang et al., 2002) , and also from infection studies using transgenic or knockout mice defective in the production of various AMPs (Moser et al., 2002; Salzman et al., 2003; Wilson et al., 1999) .
Immune modulation (may indirectly be antibacterial)
AMPs are produced by epithelial cells and by circulating immune cells including neutrophils and macrophages, and are among the first immune effectors encountered by an invading microbe (Jenssen et al., 2006) . The human cathelicidin LL-37 modulates the innate immune response by acting as a chemoattractant for neutrophils, monocytes, and mast cells (Niyonsaba et al., 2002b; Yang et al., 2000) and human ␤-defensins chemoattract leukocytes (Garcia et al., 2001a; Niyonsaba et al., 2002a; Territo et al., 1989) . ␤-Defensins also attract dendritic cells that can act directly by phagocytizing and killing pathogens (Liu, 2001) or by producing cytokines, chemokines and other AMPs that then participate in innate antimicrobial activity (Duits et al., 2002) . Thus cathelicidin, defensins and chemokines overlap in their chemotactic activity and affects on innate immunity.
Mode of action of AMPs
Membrane interaction specificity
Selective toxicity, killing bacterial pathogens without damaging host tissue, is a feature that is crucial for AMPs. However, while it has been demonstrated that AMPs can permeabilize bacterial membranes and cell walls, and that this ability correlates with their antibacterial effects, the actual mode of bacterial killing by AMPs remains an area where there is still a poor level of understanding. One clue to the potential specificity of killing by membrane disruption is that there are significant differences in the lipid composition of bacterial and eukaryotic cell membranes (Sohlenkamp and Geiger, 2016; Teixeira et al., 2012) . Bacterial membranes are rich in negatively charged phospholipids such as phosphatidylglycerol (PG), cardiolipin (CL) and phosphatidylserine (PS) that are stabilized by divalent cations such as Mg 2+ and Ca 2+ . In addition, Gram-negative bacteria have an outer membrane containing LPS that acts as a permeability barrier reducing access to the cytoplasmic membrane. In contrast to bacteria, human cell membranes are rich in zwitterionic phospholipids with a neutral net charge, such as phosphatidylethanolamine (PE), phosphatidylcholine (PC), and sphingomyelin (SM). The human AMP LL-37 can discriminate between different membranes based on their lipid constituents, preferentially inserting into lipids containing PG, typical of bacterial membranes, but not into membranes containing PC or PE, as found in human red blood cells (Neville et al., 2006) . These important differences between bacterial and eukaryotic membranes, where bacteria have anionic lipids exposed on the surface whereas eukaryotic membranes sequester anionic lipids in the monolayer facing the interior of the cell, may explain the selectivity of AMPs for bacterial membranes. Human cell membranes also contain significant amounts of cholesterol that affect the fluidity of phospholipids in the membrane, and increase the stability of the lipid bilayers (Tytler et al., 1995) . Accordingly, a number of distinguishing features including the presence of cholesterol, the membrane potential, and the asymmetric distribution of phospholipids in the membrane, may be important for reducing the binding of AMPs to human cells (Lai and Gallo, 2009 ).
Membrane and cell wall activity of AMPs
The bacteriocidal effect of AMPs is widely believed to be due to the formation of pores in the bacterial cytoplasmic membrane, resulting in a loss of control over ion flows across the membrane and cell death. There is considerable in vitro data showing that AMPs can disrupt lipid bilayers, supporting this basic model. Exactly how AMPs form pores in bacterial membranes is less certain. The initial step is believed to involve electrostatic interactions between the positively charged amino acids in AMPs and the negatively charged LPS, or phospholipid head group of the membrane, resulting in AMPs accumulating on the surface of the membrane (Epand et al., 2015) . After reaching some threshold concentration, AMPs may self-assemble on the membrane and incorporate into it creating a pore in the process. Several models for AMP-directed membrane pore formation have been suggested: (i) the barrel-stave model, proposes that peptides insert perpendicularly in the bilayer, associating together to form a pore; (ii) the carpet mechanism, proposes that peptides adsorb parallel to the bilayer and, after reaching sufficient density of coverage, produce a detergent-like effect that disintegrates the membrane; and (iii) the toroidal pore mechanism, proposes that peptides insert perpendicularly in the bilayer and induce a local membrane curvature with the pore lined partly by peptides and partly by phospholipid head groups (Melo et al., 2009) .
Recent research suggests that the interactions between different AMPs and bacterial membranes may involve much more specific interactions than suggested by these generic models of pore formation. For example, phosphatidylethanolamine (PE), present at a high concentration on the surface of bacterial membranes but sequestered on the cytoplasmic leaflet of mammalian membranes, acts as a high affinity lipid receptor for several AMPs (Phoenix et al., 2015) . Current evidence suggests that many AMPs, including the plant cyclotides, use specific receptors such as PE, in their interactions with membranes (Stromstedt et al., 2016) . Other specific components of bacterial membranes that are targeted by AMPs include LPS, lipoteichoic acid (LTA) and the peptidoglycan precursor lipid II (Schmitt et al., 2015) . Lipid II seems to be a favorite target. The antibiotic activity of the human ␤-defensin 3 (Sass et al., 2010) and human ␣-defensin 1 (de Leeuw et al., 2010; Varney et al., 2013) , relies on their selective binding of lipid II to block bacterial cell wall biosynthesis. Accordingly, the bacteriocidal activities of many human AMPs may have little or nothing to do with generic effects on the integrity of bacterial cytoplasmic membranes and more to do with specific target interactions that happen to be localized to the bacterial cell wall and/or membrane.
AMPs activity may also involve intracellular targets
AMPs have also been shown to traverse the cell membrane and to block essential cellular processes without causing extensive membrane damage (Brogden, 2005; Patrzykat et al., 2002) raising the question of whether some of their antibacterial activities are dependent on intracellular targeting. Thus, analogs of the human ␤-defensin 4 were shown to translocate across the outer and inner membranes of Escherichia coli without causing cell lysis, suggesting that the observed bacteriocidal activity might depend on cytoplasmic interactions (Sharma and Nagaraj, 2015) . Human ␣-defensin 5 was also shown to translocate into the cytoplasm of E. coli and to accumulate at the site of cell division and at the cell poles, supporting the notion that at least part of its antimicrobial activity might be exerted in the cytoplasm (Chileveru et al., 2015) . Indolicidin, a bovine cathelicidin with broad-spectrum bacteriocidal activity, has been shown not to lyse bacterial cells but to inhibit DNA synthesis (Subbalakshmi and Sitaram, 1998) and shown in vitro to interact with duplex DNA (Ghosh et al., 2014) . Analogs of buforin antimicrobial peptides were also shown to exert their bacteriocidal activity on E. coli by binding to DNA and RNA after penetrating the cell membrane (Hao et al., 2013) . One possibility is that AMP targeting can be promiscuous and dependent on local concentration, either causing lethal membrane disruption or translocation into the cytoplasm to interfere with cellular metabolism (Sugiarto and Yu, 2007) . One of the approaches to test the significance of intracellular interactions in the bacteriocidal effects of AMPs is to select for mutants with reduced susceptibility to AMPs and then genetically map the selected mutations. In the following sections this approach is described, with the twin aims of determining the probability of resistance developing in the case that AMPs are used more widely in therapy, and to gain a better understanding of the molecular targets of AMPs, whether at the cell wall, cell membrane, or intracellularly.
Intrinsic resistance to AMPs
Bacteria encounter AMPs frequently in their natural environments and have evolved mechanisms to resist their action. Intrinsic resistance to AMPs can occur via passive or inducible mechanisms. Passive AMP resistance occurs in some bacterial species including Proteus, Morganella, Providencia, Serratia, and Burkholderia as a result of an inherently more positively charged lipid A that reduces AMP interaction (Manniello et al., 1978; Viljanen and Vaara, 1984) . The induction of AMP-resistance in other bacteria is tightly regulated in response to environmental conditions and serves as a mechanism for bacterial survival in various natural environments in which they would experience the threat of AMPs. Inducible (also referred to as adaptive) resistance results in transient molecular modifications in both Gram-negative and Gram-positive bacteria (summarized in Fig. 1 ). Reversibility offsets the energetic burden imposed by many of these modifications, which largely affect the composition of the bacterial membrane. The molecular basis of inducible AMP resistance has been reviewed extensively for both Gram-negative and Gram-positive bacteria (Anaya-Lopez et al., 2013; Gunn, 2001; Kraus and Peschel, 2006; Matamouros and Miller, 2015; Nawrocki et al., 2014; Nizet, 2006; Yeaman and Yount, 2003) . A common mechanism of AMP resistance in bacteria is the incorporation of positively charged molecules into their cell surface in order to reduce the interaction and binding of cationic AMPs. Inactivation of these mechanisms results in enhanced susceptibility to AMPs, including components of the host innate immune system and often in reduced virulence.
Membrane modifications in Gram-negative bacteria
Intrinsic AMP resistance has been most extensively studied in Salmonella enterica serovar Typhimurium in which a variety of LPS modifications are triggered by environmental stimuli including nutrient starvation (McLeod and Spector, 1996) , low pH, low magnesium, and high iron (Gunn and Miller, 1996) as well as in various host tissues (Kubicek-Sutherland et al., 2015) . The PmrAB, PhoPQ and Rcs regulatory systems mediate many of these modifications in order to support bacterial survival in vivo. The addition of 4-aminoarabinose (Ara4N) to lipid A, which creates a less negatively charged LPS and reduces binding affinity of AMPs, is regulated by the pmrCAB and pmrHFIJKLM operons in S. Typhimurium (Gunn . Inactivation of pmrA or pmrB results in attenuated virulence when administered orally but not intraperitoneally indicating the importance of Ara4N modification in overcoming the innate immunity in the intestine. PmrA can also be regulated by the PhoPQ system via the protein PmrD, which prevents dephosphorylation of PmrA resulting in continued activation (Roland et al., 1994) . Other PhoPQ regulated genes that mediate AMP resistance and virulence in S. Typhimurium include slyA, encoding a virulence regulatory protein; ugtL, encoding an inner membrane protein that forms monophosphorylated lipid A; pagP, encoding an outer membrane protein involved in palmitoylation of lipid A; and yqjA, an inner membrane protein of unknown function Shi et al., 2004a,b) . The Rcs phosphorelay system regulates AMP resistance in S. Typhimurium by activating expression of the uncharacterized periplasmic protein YdeI, which is required for AMP resistance and oral virulence in mice (Erickson and Detweiler, 2006) . Other AMP resistance and virulence determinants in S. Typhimurium include surA, tolB, and pgm. SurA and TolB are involved in membrane stabilization while Pgm (phosphoglucomutase) is involved in LPS biosynthesis (Paterson et al., 2009; Tamayo et al., 2002) .
The PhoPQ system also plays a role in AMP resistance and virulence in Pseudomonas aeruginosa (Gooderham et al., 2009) , and PmrAB regulated LPS modifications confer AMP resistance in Acinetobacter baumannii (Adams et al., 2009) . In Vibrio cholerae, the almEFG operon encodes the glycylation of LPS, which confers resistance to polymyxins (Henderson et al., 2014) . In P. aeruginosa the arnBCADTEF operon mediates the addition of Ara4N to lipid A conferring AMP resistance (McPhee et al., 2003) . The anionic capsular polysaccharide of Klebsiella pneumoniae, P. aeruginosa, and Streptococcus pneumoniae, has also been shown to confer resistance to polymyxin B and human ␣-defensin 1 by binding cationic AMPs (Llobet et al., 2008) .
Membrane modifications in Gram-positive bacteria
In Gram-positive bacteria, AMP-resistance occurs following the incorporation of positively charged molecules into cell wall teichoic acids (TA), which play an essential role in cell division, morphology, adhesion, virulence and antimicrobial resistance (Brown et al., 2013) . Although critical to cellular function, the anionic properties of TAs make them a target for the binding of positively charged AMPs. Resistance to AMPs is often conferred in a transient manner via TA modifications that reduce the overall negative charge in the bacterial membrane. The GraRS (also known as aps) sensor/regulator system senses AMPs in the environment and induces AMP resistance in Staphylococcus aureus by activating the d-alanylation of TA, the incorporation of lysylphosphatidylglycerol in the bacterial membrane, and activation of the vraFG AMP transporter . d-Alanine ester modifications are made via components of the dlt operon in response to low divalent cation concentrations (Mg 2+ and Ca 2+ ) and the presence of cationic AMPs (Koprivnjak et al., 2006) . Inactivation of the dlt operon results in increased susceptibility to AMPs in S. aureus (Peschel et al., 1999) , Bacillus subtilis (Cao and Helmann, 2004) , Group A streptococci (GAS) (Kristian et al., 2005) , Group B streptococci (GBS) (Poyart et al., 2003) , Listeria monocytogenes (Abachin et al., 2002) , and Lactobacillus reuteri (Walter et al., 2007) . Similarly, the MprF protein (multiple peptide resistance factor) mediates the addition of l-lysine to membrane phospholipids thereby reducing their overall negative charge and conferring AMP resistance in S. aureus (Ernst et al., 2009) , L. monocytogenes (Thedieck et al., 2006) , and Bacillus anthracis (Samant et al., 2009 ). Inactivation of graR or mprF results in enhanced susceptibility to AMPs and attenuation of virulence in mice Li et al., 2007; Yang et al., 2012) .
Other intrinsic AMP resistance mechanisms
Besides membrane modification, other effective methods for dampening the antimicrobial effects of AMPs are efflux and proteolytic degradation. In S. Typhimurium AMPs are exported by the sap (sensitivity to antimicrobial peptides) efflux system and the putative ABC transporter encoded by the yejABEF, both of which are required for virulence in mice (Eswarappa et al., 2008; Groisman et al., 1992b) . In S. aureus, the chromosomal vraFG gene encodes the ABC transporter-dependent efflux pump, also regulated by GraRS . Also, the plasmid-encoded qacA gene encodes a proton motive force-dependent efflux pump (Kupferwasser et al., 1999) . Efflux pumps that act on AMPs have also been identified in Neisseria gonorrhoeae (Shafer et al., 1998) and Yersinia spp. (Bengoechea and Skurnik, 2000) . Proteases that degrade AMPs include PgtE in S. Typhimurium (Guina et al., 2000) and OpmT in E. coli (Stumpe et al., 1998) .
Methods to identify intrinsic AMP resistance mechanisms
To date the molecular basis of intrinsic AMP resistance has been characterized largely using gene inactivation studies. These studies have been conducted using both large-scale (genome-wide) and targeted (single gene) approaches. Screening approaches to identify genes associated with AMP resistance typically involve transposon or chemical mutagenesis of a wild type AMP-resistant bacterial isolate to create a collection of mutants, which are then screened phenotypically for resulting AMP hyper-susceptibility. Such studies have identified genes conferring AMP resistance in S. Typhimurium (Fields et al., 1989; Groisman et al., 1992b) , E. coli (Groisman et al., 1992a) , Group A Streptococcus (GAS) (Nizet et al., 2001) ; S. aureus (Peschel et al., 1999 (Peschel et al., , 2001 ; and Neisseria meningitidis (Tzeng et al., 2005) . Transposon mutagenesis can also be performed on a bacterial strain with a mutant background in order to assess the contribution of particular genes in a resistance pathway. For instance, mutagenesis was performed in S. Typhimurium on a constitutively active pmrA mutant allowing for the initial identification of non-regulatory genes conferring AMP resistance, pmrE (also known as pagA and ugd) and pmrF, both of which are involved in lipid A modification .
These large-scale screens have provided tremendous insights into the molecular basis of intrinsic resistance, however there are disadvantages to this methodology. Drawbacks from a large-scale knockout approach include the difficulty in observing small changes in AMP susceptibility that often require time-kill assays to detect; AMP-resistance mechanisms involving multiple genes are not directly assayed; and the involvement of essential genes can not be characterized. This method can also be limited by the high cost of certain AMPs, which can make large-scale phenotypic screening very expensive and the approach has thus far been largely limited to less expensive peptides. Transposon mutagenesis can also involve harsh conditions often resulting in additional unintended background mutations that are typically not accounted for in large-scale screens.
Once a gene or pathway has been identified, a subsequent more targeted approach can provide direct information about the relationship between individual genes and AMP resistance. The inactivation of individual genes of interest has helped to identify genes within a regulon that may be overlooked in a large-scale approach. Narrowing the analysis down to several genes of interest also supports the testing of resistance to a variety of AMPs, including those that are more expensive. However, this targeted approach requires prior elucidation of candidate genes and their regulatory pathways and still does not include essential genes. Lastly, the largest problem with gene inactivation studies is the inability to assess the molecular basis of acquired (stable) AMP resistance.
Acquired resistance
Methods to select for mutants with acquired AMP resistance
Considering the continued high interest in AMPs as potential therapeutic drugs for bacterial infections surprisingly few studies have tried to assess the risk of resistance development and explore the mechanisms for acquired resistance. Partly this might be explained by the long-held, and erroneous, belief that resistance to AMPs is very difficult to acquire and that it therefore is not a big concern (Batoni et al., 2011; Ghosh and Haldar, 2015; Nizet, 2006; Yeaman and Yount, 2003) . However, as several recent studies have shown, resistance to AMPs can in fact evolve at high rates (at least in vitro), generating mutants with, sometimes high, levels of resistance.
Typically two different methods have been used to select mutants with acquired resistance to AMPs (Fig. 2) . The first, and most used, method involves serial passage of bacteria in media containing AMPs at concentrations near the MIC, which are progressively increased during the course of the experiment as resistant mutants are enriched. After different time points bacteria are recovered and tested for resistance by broth micro-dilution (to obtain MICs of the AMPs) and/or time-kill assays (Lofton et al., 2013) . Generally the latter method is more sensitive in detecting small differences in susceptibility (Lofton et al., 2013) . The advantage with serial passage is that it is relatively easy to perform and that it requires low amounts of AMPs since growth volumes are small. However, disadvantages are that it only selects for high fitness mutants (i.e. the mutant spectrum will be biased) and because selection is stepwise the mutants often contain more than one mutation, necessitating subsequent genetic reconstitution experiments to confirm the role of each individual mutations. Likewise, because the selection is not lethal and growth often occurs during several hundred generations, media adaptation mutations will almost always be acquired (Lofton et al., 2013) . These mutations confer fitness increases that are unrelated to the AMP-selection and are identifiable by performing a parallel experiment in the absence of AMP. An alternative approach, and which if possible is preferable, is to perform a direct selection on agar plates containing AMP levels above the MIC. The advantages with this approach are that the mutants generally only contain one mutation (alleviating the need for genetic reconstruction, a big advantage in organisms that are genetically intractable) and that also resistant mutants with severe fitness reductions are recoverable. Furthermore, if this experiment is performed as a classical Luria-Delbruck fluctuation test with many independent cultures (Pranting and Andersson, 2010; Pranting et al., 2008; Sun et al., 2009) , this approach allows determination of mutation rates to resistance. The main problem with the use of agar plate selections is that it requires high amounts of AMPs and that many AMPs are less active/inactive in the complex environment of an agar plate (Dhawan et al., 1997) . Furthermore, if resistance evolution requires the formation of several mutations the direct selection method is unlikely to yield results, making the serial passage method preferable.
For both of the above methods, it is possible to explore additional mutational pathways and resistance mechanisms by artificially increasing the mutation rate. 
Mechanisms of acquired resistance
The molecular basis of acquired resistance has been characterized in a handful of bacterial pathogens through isolation of naturally occurring resistant isolates, serial passage in the presence of AMPs and direct plating with AMPs (summarized in Table 1 ).
Naturally occurring acquired resistance
Recently, for the first time AMP resistance has been shown to be horizontally transferable in E. coli. A plasmid containing the mcr-1 gene was shown to mediate colistin resistance by encoding a phosphoethanolamine modification to lipid A . The mcr-1 containing plasmid was initially isolated in Chinese livestock animals, and since its initial characterization the mcr-1 gene has been identified retroactively in 3 of 1267 human fecal microbiome samples taken from China prior to 2011 indicating animal to human gene transfer (Hu et al., 2016) .
In S. aureus the small colony variant (SCV) phenotype, characterized by slow growth rate, diminished transmembrane potential and altered metabolism, has been associated with resistance to several AMPs including LL-37, human ␤-defensins 2 and 3, RNase 7 and lactoferricin B (Glaser et al., 2014; Samuelsen et al., 2005b) . The SCV phenotype can be induced by the intracellular environment at a rate of 10 −3 (spontaneous rate is less than 10 −7 ) in S. aureus in order to evade the host immune response (Vesga et al., 1996) . The lactoferricin B resistant phenotype of SCVs in S. aureus was shown to be a result of reduced metabolic activity and not of reduced transmembrane potential or uptake of the peptide (Samuelsen et al., 2005b) . Glaser et al. (2014) also showed that clinically derived S. aureus SCVs as well as a hemB auxotroph displayed reduced susceptibility to LL-37 and human defensins. S. aureus has also displayed constitutive resistance to platelet microbicidal proteins (PMPs) by increasing membrane fluidity via expression of unsaturated lipids (Bayer et al., 2000) or reducing membrane potential (Yeaman et al., 1998) . Samuelsen et al. (2005a) described the rapid induction of S. aureus resistance to the AMP lactoferricin B (active form of bovine lactoferrin) with over 30-fold increase in resistance following only four serial passages in medium containing increasing concentrations of the peptide. High-level lactoferricin B resistance was maintained when passaged in medium without peptide. Following 30 passages in the absence of peptide, all strains displayed at least a partially stable resistance phenotype with elevated MICs up to 10-fold higher than wild type although the exact mechanism of resistance was not defined. Lactoferricin B resistant mutants also displayed low-level cross-resistance to indolicidin and magainin. These experiments suggest that in S. aureus the acquisition of lowlevel stable resistance can be achieved rapidly, within as little as four passages in the presence of lactoferricin B, while high-level stable resistance requires the acquisition of multiple mutations over time. Perron et al. (2006) showed that stable AMP resistance can arise in E. coli and Pseudomonas fluorescens following continuous exposure (600-700 generations) to gradually increasing concentrations of the AMP pexiganan, a magainin analog currently in clinical development. Pexiganan resistance was observed with 32-to 512-fold and 2-to 64-fold increase in resistance to the parental strains for P. fluorescens and E. coli, respectively without an in vitro fitness cost. However, the exact mechanism of resistance was not determined. Similarly, it was shown that S. aureus could develop stable AMP resistance following serial passage in medium containing increasing concentrations of pexiganan (Habets and Brockhurst, 2012) . These mutants often displayed 10-to 50-fold increased resistance to pexiganan and cross-resistance to human ␣-defensin HNP1. The larger the level of pexiganan resistance, the higher the in vitro fitness cost. Further serial passage in the absence of pexiganan resulted in compensatory mutations ameliorating the fitness cost while maintaining AMP resistance, but the molecular basis of AMP resistance was not defined. This study suggests that the costs associated with pexiganan resistance in S. aureus can be easily compensated resulting in the persistence of mutants capable of evading critical components of the human innate immune system. Acquired AMP resistance in S. Typhimurium has been examined by following continuous exposure (∼500 generations) to increasing concentrations of LL-37 (a human cathelicidin), CNY100HL (derivative of human C3 complement peptide CNY21), or wheat germ histones (WGH) (Lofton et al., 2013) . This resulted in the rapid isolation of stable resistant mutants that also displayed 2-to 4-fold increases in resistance to the AMPs not used for selection. AMP resistant isolates where shown to contain mutations in two-component regulatory systems (pmrB or phoP) or in LPS biosynthesis pathways (waaY, also referred to as rfaY). phoP mutants containing a single amino acid substitution showed similar levels of resistance to all three AMPs tested and had a fitness cost in vitro, however no significant virulence defect was detected in a mouse model of sepsis (Lofton et al., 2015) . The phoP mutant also displayed a reduced O-antigen chain length, enhanced tolerance of low pH and bile, and increased pagP expression regardless of environmental Mg 2+ ion concentrations, indicating a constitutively active phenotype. Mutations in pmrB, single amino acid substitutions, occurred without an impact on bacterial fitness in vitro or in vivo in mice via intraperitoneal infection, yielding low-level AMP resistance. Activation of the PmrAB two-component regulatory system supports the Ara4N modification of lipid A, resulting in reduced negative charge and diminished AMP binding. An inactivating frameshift mutation in waaY also resulted individually in low-level AMP resistance without an impact on bacterial fitness in vitro, however in a mouse model of sepsis this mutation resulted in minor attenuation. Disruption of waaY results in reduced heptose phosphorylation of the LPS core, thereby diminishing the interaction between AMPs and the bacterial membrane. Although these individual mutations each conferred only minor enhancements in AMP resistance, combining all three mutations in a single mutant further increased AMP resistance. pmrB and waaY mutations appeared together in two of four isolates following serial passage with LL-37 or CNY100HL indicating a possible epistatic effect between these mutations both of which lead to a reduction in AMP interaction with LPS.
Serial passage
Direct plating
Roland et al. isolated spontaneous AMP resistant S. Typhimurium by directly plating on agar plates containing various concentrations of polymyxin E (colistin). Characterization of the resulting AMP-resistant mutants yielded a mutant containing a pmrA mutant allele (pmrA505) that displays constitutive activation of PmrAB leading to increased Ara4N and phosphoethanolamine covalent modification of LPS. pmrA505 displays a 1000-fold increase in resistance to polymyxin B and a 2-to 4-fold increase in resistance to neutrophil proteins (Roland et al., 1993) . Colistin-resistant mutants in S. Typhimurium were also obtained by direct plating on agar containing colistin at a concentration 10 or 50 times the MIC of wild type (Sun et al., 2009 ). Spontaneous resistant mutants displayed 2-to 35-fold increased colistin resistance with little to no fitness cost in a mouse model of sepsis. 44 independent mutants were characterized and 27 different missense mutations were identified in pmrA or pmrB, the two-component regulatory system. The colistin-resistant mutants displayed 2-to 15-fold increases in expression of pmrH indicating a dysregulation of pmrAB-regulated genes. Stable colistin resistance following direct plating was also observed in A. baumannii following the complete loss of LPS due to the inactivation of one of three genes involved in lipid A biosynthesis (lpxA, lpxD, or lpxC) (Moffatt et al., 2010) .
Similarly, a PhoQ conditionally constitutive allele (phoQ24 or pho-24) displayed ∼10-fold increase in phoP-activated genes (pags) (Miller and Mekalanos, 1990) . When grown in low levels of Mg 2+ , the phoQ24 allele confers polymyxin resistance as a result of increased expression of PmrAB (Gunn and Miller, 1996) . A similar phenotype was observed following over-expression of dltABCD in wild-type S. aureus, which increases d-alanylation of TA and reduces cell surface negative charge (Peschel et al., 1999) .
Stable resistance to the pig cathelicidin PR-39 occurred in S. Typhimurium following direct plating on PR-39 containing agar at a concentration 1.5 times the MIC of wild type (Pranting et al., 2008) . The resulting spontaneous PR-39 mutants were stable and displayed 2.5 to 3.5 fold increases in PR-39 resistance over wild type. All of the AMP resistant mutants isolated contained mutations in sbmA, a putative ABC transporter. The isolated mutants displayed similar phenotypes to that of a sbmA strain indicating that a loss of function genotype resulting in reduced PR-39 uptake into the cell is responsible for the increased AMP resistance. The inactivation of sbmA and the resulting PR-39 resistance did not confer a fitness cost in vitro or in a mouse model of sepsis.
S. Typhimurium mutants resistant to protamine, an argininerich AMP isolated from salmon sperm cells, were isolated by direct plating on agar containing protamine at a concentration of around 3 times the wild type MIC (Pranting and Andersson, 2010) . Spontaneous mutants were 2-to 20-fold more resistant to protamine than wild type, and displayed cross-resistance to other AMPs (colistin, lactoferricin, human ␣-defensin HNP1). Resistance mutations were identified as deletions, nonsense or missense in haem biosynthesis (hemA, hemB, hemC, hemL) with 14 different mutations in four steps of haem biosynthesis were observed indicating that the lack of an end product in this pathway is responsible for protamine resistance. Mutations in the hem genes often result in defects in electron transport and respiration, which results in slow growth, reduced membrane potential and thus lowered affinity for binding and uptake of AMPs. All protamine-resistant mutants displayed large defects in bacterial fitness with relative growth rates ranging from 0.25 to 0.85 as compared to the wild type. The tremendous fitness cost resulted in instability of the protamine resistance in some mutants, particularly hemC and hemA mutants, and compensatory evolution by serial passage in the absence of protamine resulted in the loss of protamine resistance. Three mutants displayed nonsense mutations in cydC, a cysteine/glutathione ABC transporter thought to be involved in maintaining cellular redox balance. A cydC mutant would therefore display reduced membrane potential as well, resulting in AMP resistance. Spontaneous high-level bacteriocin resistance (over 2000-fold) occurred in L. monocytogenes following direct plating due to increased expression of two putative ␤-glucoside-specific phosphotransferase systems leading to reduced interaction with AMPs (Gravesen et al., 2002) .
What determines the risk of acquiring resistance to AMPs?
As for any type of drug resistance, the rate by which AMP resistance would emerge and spread in a population of bacteria in a natural setting is determined by a complex interplay of several different factors, including the mutation supply rate; the fitness of the resistant mutant at different AMP concentrations and the strength of the selective pressure (AMP levels) (Hughes and Andersson, 2015) . Also, the occurrence of compensatory evolution where fitness costs might be reduced by additional mutations, and epistatic interactions involving resistance genes and drugs (Hughes and Andersson, 2015 ) that may generate cross-resistance and/or collateral sensitivity, complicates the picture even further. In addition, numerous other epidemiological factors (e.g. host population structure, density, immunity, etc.) will affect how a putative AMP resistant clone would spread in a population. Several of the above parameters have been defined for antibiotic and antiviral resistances but with regard to AMP resistance few have been explored in any detail (summarized in Table 2 ).
Mutation supply rate
The generation of genetic heterogeneity, in this case mutants that are resistant/less susceptible to AMPs, in a bacterial population is largely determined by the mutation supply rate, the product of the population size and rates of mutation (or HGT) to AMP resistance. Mutation rates to AMP resistance have been measured in several cases and they are typically in the range of 10 −7 to 10 −6 per generation per cell (Pranting and Andersson, 2010; Pranting et al., 2008; Sun et al., 2009) , making them comparable to antibiotics (10 −5 to 10 −10 per generation per cell). Population sizes within an infected human are generally poorly known but in a few cases we have numbers for the total bacterial population size. For example, for urinary tract infections the total population sizes in a full bladder of 300 ml is in the range of 10 6 -10 10 per bladder and for pulmonary tuberculosis infections the number of bacteria per ml of sputum can be 10 5 -10 6 and even higher in the lungs (Hughes and Andersson, 2015) . Similarly, for meningitis and bronchitis the bacterial counts can be as high as 10 9 per ml, and overall these data suggest that the total bacterial population sizes in an infected individual typically is so high that pre-existing AMP resistant mutants are expected to be present (i.e. population size x mutation rate >1) when treatment is initiated.
Mutant fitness
The fitness of a drug-resistant pathogen (in the absence and presence of drug) is a key parameter in determining evolutionary success-i.e. the probability that it will emerge, fix, transmit and remain-within a host population, as has been demonstrated in different studies for antibiotic resistant bacteria . With regard to fitness measurements of AMP resistant mutants data is scarce and only a few studies have explored this in some detail (Lofton et al., 2013 (Lofton et al., , 2015 Pranting and Andersson, 2010; Pranting et al., 2008) . As is generally observed for antibiotic resistant mutants, AMP resistant variants show some type of reduction in fitness, even though cases are known when with the assays used, the resistant mutants appeared as fit as the congenic susceptible strain (Pranting et al., 2008) . For example, PR-39 resistant S. Typhimurium mutants showed no apparent reduction in fitness as measured by growth rate, starvation survival and growth in mice. In other cases, S. Typhimurium mutants resistant to colistin, LL-37, CNY 100HL and wheat germ histones, fitness was significantly reduced but the reductions were for some mutants relatively minor, suggesting that these mutants might persist quite well in a host population, even without a selective pressure (Lofton et al., 2013 (Lofton et al., , 2015 . Yet for protamine resistant S. Typhimurium mutants the reductions were so severe that it is unlikely that they could remain in the host population without a strong selection (Pranting and Andersson, 2010) .
Selection strength
Bacterial pathogens are, as a result of treatments, exposed to a wide range of antibiotic concentrations, generating a variable range of selective pressures. As shown by recent studies, not only concentrations well above MIC (lethal selection) can select for resistance but mutants may also emerge during non-lethal selection far below the MIC, where their rate of enrichment is determined by the fitness difference between susceptible and resistant cells (Gullberg et al., 2011) . Since only a few peptide antibiotics (e.g. colistin) have had any widespread clinical use, and as of yet no in vitro studies have been performed to study selection at different AMP concentrations, it is difficult to assess the impact of selection strength on which mutant types emerge. It is notable that for AMPs, selection for resistant mutants could occur at two levels: (i) due to therapeutic use of AMPs (which might generate very strong selective pressures), and (ii) due to continuous selection provided by AMPs produced in the human body and to which bacterial pathogens can be exposed. At present, we know that the pressure exerted by therapeutic use is weak (simply because few AMPs are used clinically) but the pressure exerted by human-specific AMPs is largely unknown. However, one recent study showed that for a waaY mutant resistant to several AMPs the dosage of LL-37 (0.1-1.5 mg/L) required to select for and maintain the mutant in the population is similar to the concentrations of AMPs found in, for example, secretions near host epithelial cells (Lofton et al., 2013) . This finding implies that naturally produced AMPs will exert significant selective pressures. However, the deleterious nature of this particular waaY mutation (reduced tolerance of serum, acidic conditions, and survival in a mouse model of sepsis) likely explains its absence in pathogenic isolates (Lofton et al., 2015) .
Compensatory evolution
Most mutations that occur in any organism are deleterious but compensatory evolution, where the costs are reduced or eliminated by additional mutations, might increase the probability of maintenance. A number of experimental and clinical studies have shown that the fitness cost of antibiotic resistance can be efficiently and rapidly reduced by compensatory mutations and that compensated mutants can rapidly sweep a resistant population of bacteria (Andersson and Hughes, 2010) . To what extent this process will influence evolution will depend on the mutation rates of compensation, the fitness of compensated mutants and the population size of the resistant mutant. One of the few studies of compensatory evolution involving AMPs was made using pexiganan and S. aureus but the actual mutations selected were not determined (Habets and Brockhurst, 2012) .
Epistatic interactions
Recent data from bacteria show that epistasis between resistance mutations is pervasive and that it might have an impact on resistance evolution (Hughes and Andersson, 2015) . For example, combinations of fitness-reducing chromosomal resistance mutations and/or resistance plasmids can either generate no epistasis, positive epistasis (a double mutant has a higher fitness than expected from the sum of costs of individual mutations), or negative epistasis (a double mutant has a lower fitness than expected from the sum of costs of individual mutations). All of these types of epistasis have been observed in experimental studies. At present, this type of epistasis has not been systematically studied for AMP resistance mutations.
Another type of epistasis involves the phenomenon where resistance to one drug alters susceptibility to other drugs. Thus, resistance to one drug class might either increase resistance to another (cross-resistance), or result in increased susceptibility (Macvanin and Hughes, 2005) , so-called collateral sensitivity. Recent large-scale studies have shown that both are common phenomena for antibiotic resistance and they imply that collateral sensitivity can potentially be applied to clinical situations to reduce the rate of resistance evolution (Imamovic and Sommer, 2013; Munck et al., 2014) . Thus, treatment would combine two drugs where resistance evolution to one drug increases the susceptibility to the other. Again, for AMP resistant mutants the extent of collateral sensitivity for different AMPs and/or antibiotics has not been extensively explored, even though a few cases have been reported (Berti et al., 2015; Garcia-Quintanilla et al., 2015) .
Therapeutic use of AMPs
Widespread antibiotic resistance has led to the urgent need for discovery of novel antimicrobials to treat bacterial infections. The broad-spectrum bactericidal activity of AMPs makes them a promising candidate for therapeutic use. There are only a handful of AMPs currently in clinical use, and of these, polymyxin B and colistin (polymyxin E) are the most characterized in a clinical setting (Falagas and Kasiakou, 2005; Landman et al., 2008; Zavascki et al., 2007) . The polymyxins are produced by the bacterium Bacillus polymyxa and were introduced into clinical practice in the 1950s. The polymyxins have been administered intravenously to treat multi-drug resistant infections caused by Gram-negative pathogens, as an aerosol to treat bronchopulmonary infections, and intraventricularly to treat meningitis (Landman et al., 2008) . In addition to its use for systemic treatment of complicated infections, polymyxin B is used in topical formulations to treat and prevent skin, eye and ear infections. The high incidence of nephrotoxicity and neurotoxicity associated with intravenous administration has resulted in limited usage and study of these drugs over the past 50 years (Falagas and Kasiakou, 2006) . Regardless, the emergence of multi-drug resistant pathogens has led to an increase in the therapeutic use of polymyxins despite limited pharmacological and susceptibility studies. Conflicting clinical breakpoints have emerged due to the sensitivity of polymyxins, like other AMPs, to environmental conditions, resulting in discrepancies between in vitro and in vivo efficacy. These discrepancies have hampered the clinical development of AMPs to date (Falagas and Kasiakou, 2005; Landman et al., 2008; Zavascki et al., 2007) .
Currently, there are many AMPs in clinical development for the treatment of various bacterial pathogens, but the majority of these are intended for topical use only (Table 3) . This is likely a direct result of the toxicity observed following systemic administration of polymyxin B and colistin (Falagas and Kasiakou, 2006) . The only AMP in clinical trials for intravenous administration is human-derived Lactoferrin 1-11 (hLF1-11) to treat life-threatening infections that occur in stem cell transplantation patients. Although a study has shown that hLF1-11 is well-tolerated in single and multiple doses as high as 5 mg following intravenous administration (Velden et al., 2009) , it is unclear whether this dose will be sufficient to treat an infection since colistin has been administered up to a total of 720 mg per day in 3 divided doses (Michalopoulos et al., 2005) .
Aside from hLF1-11, there is an AMP-derivative from the human innate immune system in phase II clinical trials. OP-145, derived from the human cathelicidin LL-37, and formulated in eardrops, is being tested to treat chronic bacterial ear infections (Malanovic et al., 2015) . Other AMPs derived from naturally occurring animal immune components include Pexiganan, Iseganan and Omiganan. Pexiganan is an analog of magainin, an AMP originally isolated from the skin of the African clawed frog, that has gone through clinical trials twice to treat diabetic foot ulcers and is currently in phase III (Lamb and Wiseman, 1998; Lipsky et al., 2008) . Another animalderived AMP is a synthetic protegrin originally isolated from pig leucocytes termed Iseganan developed as a rinse for the potential treatment of mucositis, as an aerosol to treat respiratory infections, and as a gel to treat pneumonia (Toney, 2002) . Omiganan is a derivative of indolicidin, which was isolated from bovine neutrophils and is in phase II/III clinical trials to treat skin infections. Aside from naturally occurring AMPs, there are also several purely synthetic AMPs in clinical trials (Melo et al., 2006) . The synthetic AMP LTX-109 is in phase II trials for the treatment of uncomplicated Gram-positive skin infections as well as to prevent nasal carriage of S. aureus (Nilsson et al., 2015) . C16G2 is another synthetic AMP in phase II trials indicated for the prevention of tooth decay caused by Streptococcus mutans (Kaplan et al., 2011) . Aside from the direct administration of antimicrobial peptides, there are several ongoing clinical studies aimed at modulating the expression of AMPs by the body to boost the innate immune response (Table 4) . Many recent findings have elucidated the effects of dietary nutrients on modulating the innate immune response, including the expression of AMPs, in order to assess the potential of utilizing such dietary supplements as therapeutics. Since many microbial infections are associated with inhibition of the innate immune response (Diacovich and Gorvel, 2010) , it is thought that enhancing the immune system will be an effective strategy to combat infection. Vitamin D3 has been shown to directly regulate expression of the human antimicrobial peptides LL-37 and ␤-defensin 2 (Wang et al., 2004; Weber et al., 2005) . There are many ongoing clinical trials aimed at elucidating the utility of vitamin D supplements in combating bacterial diseases ranging from uncomplicated diarrheal diseases to life-threatening pulmonary tuberculosis. Other compounds that have been shown to induce expression of host antimicrobial peptides include pimecrolimus applied topically for the treatment of dermatitis (eczema) (Buchau et al., 2008) and phenylbutyrate administered orally to treat various bacterial infections (Steinmann et al., 2009 ).
There are also AMPs used in the clinic with indications other than as antimicrobials. For example, protamine has been used clinically as a heparin antagonist to prevent blood clotting during cardiac surgery, vascular surgery, and interventional radiology. Recently, protamine has been proposed as a drug to treat obesity due to its ability to inhibit lipase activity and decrease the absorption of dietary fat (Duarte-Vazquez et al., 2009) . Routine clinical use of protamine will inevitably result in bacterial exposure and subsequent development of resistance, regardless of whether its intended use is as an antimicrobial or not. Pranting and Andersson (2010) have already shown in S. Typhimurium that protamineresistant mutants display cross-resistance to a variety of other AMPs (including components of the human innate immune system) as well as to clinically prescribed antibiotics (gentamicin and streptomycin), which would make infections more persistent and difficult to treat. The indiscriminate modulation of host AMP production is not without its own consequences. In immunocompromised individuals or those with inherent deficiencies in AMP production, the induction of endogenous AMPs may be beneficial in circumventing bacterial infections. However, artificially stimulating the production of AMPs will increase the exposure of bacterial pathogens to these agents. The exact amount of AMP expression will be difficult to control, and since exposure to high-levels of AMPs often correspond with toxic side effects there will likely be prolonged bacterial exposure to sub-inhibitory concentrations of AMPs. The ramifications of such exposure on the development of AMP resistance and bacterial pathogenesis are not yet understood.
The clinical utility of AMPs is also plagued by issues with the inherent instability of peptides, their susceptibility to proteolytic degradation, the cost of peptide production and purification, and the high association of toxic side effects which have been reviewed previously (Bradshaw, 2003; Marr et al., 2006; Vaara, 2009) . Another hindrance to the development of AMPs as therapeutics has been a general lack of mechanistic understanding manifested in the fact that despite high in vitro activity, some AMPs display little to no activity when tested under physiological relevant conditions (Marr et al., 2006) . Despite these obstacles, clinical development of AMPs to treat bacterial infections is on the rise. Although some of these peptides are not naturally derived, several studies have already shown that AMP-resistant bacterial mutants display broad cross-resistance to a variety of AMPs with different structures and modes of action. Therefore, routine clinical administration of AMPs to treat bacterial infections may select for resistant mutants more capable of evading the innate immune system. Immune evasion will likely enhance bacterial persistence and thus the need for alternate antimicrobial therapies ultimately resulting in further antibiotic use and selection for multi-drug resistant pathogens (Fig. 3) .
Concluding remarks
It is clear that at present we have a relatively limited understanding of how bacteria would acquire resistance to different AMPs, were they to be used therapeutically. Thus, few studies have examined how rapidly resistance appears and how the resistance mechanisms would impact fitness and virulence of the mutants. However, from the limited number of studies done we can also conclude that (i) it is not difficult for bacteria to acquire AMP resistance by mutation, (ii) a number of mechanisms exist by which this can occur, (iii) some of these mechanisms are not associated with any extensive loss of fitness, and (iv) often these resistance mutations confer cross-resistance to human AMPs that are part of innate immunity.
The latter is a point of special concern since it might imply that therapeutic use of AMPs could select for mutants that become resistant to key components of our own immune system. This potential problem has been pointed out by several researchers and with more data being available on acquired resistance mechanisms and crossresistance it seems clear that this is something that need to be carefully studied and monitored when AMPs are increasingly used in clinical settings.
